Table 1.
Demographic and tumor characteristics of patients.
| Characteristic | Number (%) |
|---|---|
| Age (years) | |
| Mean ± standard deviation | 55.4 ± 11.8 |
| Median | 56.0 |
| Sex | |
| Female | 42 (42) |
| Male | 58 (58) |
| ECOG PS | |
| PS 0 | 8 (8) |
| PS 1 | 53 (53) |
| PS 2 | 36 (36) |
| PS 3 | 3 (3) |
| Histopathology type | |
| Adenocarcinoma (NOS) | 89 (89) |
| Mucinous adenocarcinoma | 10 (10) |
| Signet ring adenocarcinoma | 1 (1) |
| Site of primary cancer | |
| Right-side | 24 (24) |
| Left-side | 76 (76) |
| Stage at diagnosis | |
| I | 2 (2) |
| II | 5 (5) |
| III | 29 (29) |
| IV | 64 (64) |
| KRAS status | |
| Wild | 44 (44) |
| Mutant | 66 (66) |
| Site of metastasis | |
| Liver | 51 (51) |
| Lung | 41 (41) |
| Lymph nodes | 32 (32) |
| Peritoneum | 18 (18) |
| Number of metastatic sites | |
| 1 site | 21 (21) |
| 2 sites | 33 (33) |
| >2 sites | 46 (46) |
| Number of metastatic lesions | |
| 1–2 lesions | 11 (11) |
| 3–5 lesions | 26 (26) |
| >5 lesions | 63 (63) |
| Lines of chemotherapy and biologic agents | |
| Oxaliplatin | 100 (100) |
| Irinotecan | 100 (100) |
| Capciabine | 5 (5) |
| 5FU/leucovorin | 2 (2) |
| Regorafenib | 10 (10) |
| Cetuximab | 25 (25) |
| Panitumumab | 3 (3) |
| Bevacizumab | 49 (49) |
ECOG PS: Eastern Cooperative Oncology Group performance status; NOS: not otherwise specified; Ad: adenocarcinoma; right-side: ascending+transverse colon; left-side, descending colon+Sigmoid+rectum.